{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:32:35Z","timestamp":1780047155959,"version":"3.53.1"},"reference-count":27,"publisher":"Japan Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1507\/endocrj.ej19-0034","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T22:03:47Z","timestamp":1557957827000},"page":"683-689","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience"],"prefix":"10.1507","volume":"66","author":[{"given":"Katsunori","family":"Manaka","sequence":"first","affiliation":[{"name":"Department of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taroh","family":"Iiri","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan"},{"name":"Department of Pharmacology, St. Marianna University School of Medicine, Kawasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Makita","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Dong BJ (2005) Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther 27: 1725\u20131751.","DOI":"10.1016\/j.clinthera.2005.11.015"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Tominaga Y, Kakuta T, Yasunaga C, Nakamura M, Kadokura Y, et al. (2016) Evaluation of parathyroidectomy for secondary and tertiary hyperparathyroidism by the parathyroid surgeons\u2019 society of Japan. Ther Apher Dial 20: 6\u201311.","DOI":"10.1111\/1744-9987.12352"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Takeuchi Y, Takahashi S, Miura D, Katagiri M, Nakashima N, et al. (2017) Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism. J Bone Miner Metab 35: 616\u2013622.","DOI":"10.1007\/s00774-016-0797-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, et al. (2016) The American Association of Endocrine Surgeons Guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 151: 959\u2013968.","DOI":"10.1001\/jamasurg.2016.2310"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, et al. (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99: 3561\u20133569.","DOI":"10.1210\/jc.2014-1413"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, et al. (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90: 135\u2013141.","DOI":"10.1210\/jc.2004-0842"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Peacock M, Bilezikian JP, Bolognese MA, Borofsky M, Scumpia S, et al. (2011) Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab 96: E9\u2013E18.","DOI":"10.1210\/jc.2010-1221"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Saponaro F, Faggiano A, Grimaldi F, Borretta G, Brandi ML, et al. (2013) Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. Clin Endocrinol (Oxf) 79: 20\u201326.","DOI":"10.1111\/cen.12108"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Fukagawa M, Shimazaki R, Akizawa T, Evocalcet study group (2018) Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 94: 818\u2013825.","DOI":"10.1016\/j.kint.2018.05.013"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10 Kovacs KA, Gay J (1998) Remission of primary hyperparathyroidism due to spontaneous infarction of a parathyroid adenoma. Case report and review of the literature. Medicine 77: 398\u2013402.","DOI":"10.1097\/00005792-199811000-00006"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6: 913\u2013921.","DOI":"10.2215\/CJN.06040710"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Yamada S, Tokumoto M, Taniguchi M, Toyonaga J, Suehiro T, et al. (2015) Two years of cinacalcet hydrochloride treatment decreased parathyroid gland volume and serum parathyroid hormone level in hemodialysis patients with advanced secondary hyperparathyroidism. Ther Apher Dial 19: 367\u2013377.","DOI":"10.1111\/1744-9987.12292"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Lomonte C, Vernaglione L, Chimienti D, Bruno A, Cocola S, et al. (2008) Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism? Clin J Am Soc Nephrol 3: 794\u2013799.","DOI":"10.2215\/CJN.04150907"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Tatsumi R, Komaba H, Kanai G, Miyakogawa T, Sawada K, et al. (2013) Cinacalcet induces apoptosis in parathyroid cells in patients with secondary hyperparathyroidism: histological and cytological analyses. Nephron Clin Pract 124: 224\u2013231.","DOI":"10.1159\/000357951"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, O\u2019Fallon W, et al. (1999) Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 14: 1700\u20131707.","DOI":"10.1359\/jbmr.1999.14.10.1700"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, et al. (2008) The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93: 3462\u20133470.","DOI":"10.1210\/jc.2007-1215"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, et al. (2009) Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 94: 4860\u20134867.","DOI":"10.1210\/jc.2009-1472"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Eller-Vainicher C, Palmieri S, Cairoli E, Goggi G, Scillitani A, et al. (2018) Protective effect of denosumab on bone in older women with primary hyperparathyroidism. J Am Geriatr Soc 66: 518\u2013524.","DOI":"10.1111\/jgs.15250"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, et al. (2004) Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89: 3319\u20133325.","DOI":"10.1210\/jc.2003-030908"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Sankaran S, Gamble G, Bolland M, Reid IR, Grey A (2010) Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. J Clin Endocrinol Metab 95: 1653\u20131662.","DOI":"10.1210\/jc.2009-2384"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Khan AA, Bilezikian JP, Kung A, Dubois SJ, Standish TI, et al. (2009) Alendronate therapy in men with primary hyperparathyroidism. Endocr Pract 15: 705\u2013713.","DOI":"10.4158\/EP08178.ORR"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Faggiano A, Di Somma C, Ramundo V, Severino R, Vuolo L, et al. (2011) Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine 39: 283\u2013287.","DOI":"10.1007\/s12020-011-9459-0"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Yeh MW, Zhou H, Adams AL, Ituarte PH, Li N, et al. (2016) The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism: an observational study. Ann Intern Med 164: 715\u2013723.","DOI":"10.7326\/M15-1232"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle J (2006) A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest 29: 511\u2013515.","DOI":"10.1007\/BF03344140"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Shah VN, Shah CS, Bhadada SK, Rao DS (2014) Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25 (OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf) 80: 797\u2013803.","DOI":"10.1111\/cen.12398"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Walker M, Cong E, Lee J, Kepley A, Zhang C, et al. (2015) Low vitamin D levels have become less common in primary hyperparathyroidism. Osteoporos Int 26: 2837\u20132843.","DOI":"10.1007\/s00198-015-3199-6"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Okazaki R, Ozono K, Fukumoto S, Inoue D, Yamauchi M, et al. (2017) Assessment criteria for vitamin D deficiency\/insufficiency in Japan: proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research and the Japan Endocrine Society [Opinion]. J Bone Mineral Metab 35: 1\u20135.","DOI":"10.1007\/s00774-016-0805-4"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/8\/66_EJ19-0034\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T03:43:00Z","timestamp":1567222980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/8\/66_EJ19-0034\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej19-0034","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}